Form 10-Q · Quarterly report
Baxter International 10-Q, filed Jul 30, 2026
- Filed
- CIK
- 0000010456
- Accession no.
- 0001628280-26-051118
Summary
Baxter International reported second-quarter 2026 net income attributable to stockholders of $126 million, or $0.24 per diluted share, up from $91 million, or $0.18 per diluted share a year earlier, as net sales rose 5% to $2.96 billion. Special items adversely impacted net income attributable to Baxter stockholders by $155 million, or $0.30 per diluted share.
Key points
- Second-quarter net sales were $2.960 billion, up 5% at actual rates and 5% at organic sales growth from the prior-year period.
- Six-month 2026 net income attributable to Baxter stockholders was $111 million, or $0.21 per diluted share, compared with $217 million, or $0.42 per diluted share in the first six months of 2025.
- Special items adversely impacted six-month 2026 net income attributable to Baxter stockholders by $360 million, or $0.70 per diluted share.
- Baxter temporarily stopped distributing and installing Novum LVP in the U.S. and Canada except in cases of medical necessity, and expects no meaningful Novum LVP sales while the holds are in effect; Spectrum IQ remains an alternative.
Written by an AI model from the filing text. It can be incomplete or wrong; the filing on SEC.gov is the record.
From the filing
Item 2. Management’s Discussion RESULTS OF OPERATIONS Net income (loss) attributable to Baxter stockholders for the three months ended June 30, 2026 was $126 million, or $0.24 per diluted share, compared to $91 million, or $0.18 per diluted share for the three months ended June 30, 2025. For the three months ended June 30, 2026, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $155 million, or $0.30 per diluted share. For the three months ended June 30, 2025, our results included special items that adversely impacted net income (loss) attributable to Baxter stockholders by $185 million, or $0.36 per diluted share. …
An excerpt of the text as filed with the SEC, cut for length.
Readster writes AI-generated summaries of public filings for research purposes only. Summaries can be incomplete or wrong — check the original filing on SEC.gov before relying on it. Nothing here is investment, legal or medical advice.